Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

Recombinant FGFR3 Antibody - Primary antibody, specific to FGFR3, Rabbit IgG

Features and benefits
  • Short Overview:

    Recombinant; Rabbit anti Human FGFR3 Antibody; WB, IHC, ICC, IF; Unconjugated

  • Species reactivity(Reacts with): Human
  • Isotype: Rabbit IgG
    Application:
  • IF/ICC
  • IHC
  • WB
Item Number
Ab103377
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab103377-10μl
10μl
In stock
$66.90
Ab103377-50μl
50μl
In stock
$199.90
Ab103377-100μl
100μl
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$329.90
Ab103377-1ml
1ml
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,399.90
Add to Wish List Compare
Bulk Order  DATASHEET

Recombinant; Rabbit anti Human FGFR3 Antibody; WB, IHC, ICC, IF; Unconjugated

View related series
Click to view target information: FGFR3
Accession#:P22607 FGFR3 Gene ID:2261

Basic Description

Product NameRecombinant FGFR3 Antibody - Primary antibody, specific to FGFR3, Rabbit IgG
SynonymsACH antibody; CD 333 antibody; CD333 antibody; CD333 antigen antibody; CEK 2 antibody; CEK2 antibody; FGFR 3 antibody; FGFR-3 antibody; FGFR3 antibody; FGFR3_HUMAN antibody; Fibroblast growth factor receptor 3 (achondroplasia thanatophoric dwarfism) antib
Specifications & PurityExactAb™, Validated, Recombinant, 0.3 mg/mL
Host speciesRabbit
SpecificityFGFR3
ImmunogenA synthetic peptide derived from human FGFR3 (AA 793-806)
Positive ControlWB: Hep G2 and HEK293 cell lysates. IHC: Human tonsil tissue. ICC/IF: HeLa cells.
ConjugationUnconjugated
GradeExactAb™, Recombinant, Validated
Product Description

Rabbit anti Human FGFR3 Antibody, Recombinant, could be used for WB, IHC, ICC/IF and so on.
Application
WB: 1/500-1/1000
IHC: 1/50-1/100
ICC/IF: 1/50-1/200
Protein Function
Receptor for acidic and basic fibroblast growth factors. Preferentially binds FGF1.

Product Properties

IsotypeRabbit IgG
Purification MethodAntigen affinity purified
FormLiquid
Concentration0.3 mg/mL
Storage TempStore at -20°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at 4℃ short term (1-2 weeks). Store at -20℃ long term (24 months). Upon delivery aliquot. Avoid freeze/thaw cycle.

Images

Recombinant FGFR3 Antibody (Ab103377) - Western Blot
All lanes: Recombinant FGFR3 Antibody (Ab103377) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution

Predicted band size: 88 kDa
Observed band size: 70, 123 kDa
Exposure time: 8.2 s

Recombinant FGFR3 Antibody (Ab103377) - IF/ICC
Immunocytochemistry analysis of FGFR3 (green) in HeLa using Recombinant FGFR3 Antibody (Ab103377), and cells were counterstained with DAPI (blue). 

Recombinant FGFR3 Antibody (Ab103377) - IHC
Immunohistochemistry analysis of paraffin-embedded Human tonsil using Recombinant FGFR3 Antibody (Ab103377). High-pressure and temperature Sodium Citrate pH 6.0 was used for antigen retrieval.

Associated Targets(Human)

FGFR3 Tclin Fibroblast growth factor receptor 3 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
FGFR3 Tclin Fibroblast growth factor receptor 3 (7811 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FGFR3 Tclin Fibroblast growth factor receptor (331 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FGFR3 Tclin Cereblon/FGFR3 (3 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Application

ApplicationDilution info
WB

1/500-1/1000

ICC/IF

1/50-1/200

IHC

1/50 - 1/100

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

2 results found

Lot NumberCertificate TypeDateItem
ZJ24F0102379Certificate of AnalysisJan 10, 2024 Ab103377
ZJ24F0102378Certificate of AnalysisJan 10, 2024 Ab103377

Related Documents

 SDS

 Specification Sheet

FAQs and Articles

FAQ
Immunohistochemical staining protocol for frozen samples (IHC-Fr)
Categories: Protocols
Tags:
IHC Monoclonal antibodies Immunohistochemistry Frozen section Recombinant Antibodies
Immunohistochemistry (IHC) staining antigen retrieval protocol
Categories: Protocols
Tags:
IHC Monoclonal antibodies Immunohistochemistry Recombinant Antibodies Antigen Retrieval

References

1. Huber K, Brault L, Fedorov O, Gasser C, Filippakopoulos P, Bullock AN, Fabbro D, Trappe J, Schwaller J, Knapp S et al..  (2012)  7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes..  J Med Chem,  55  (1): (403-13).  [PMID:22136433]
2. Olsen SK, Ibrahimi OA, Raucci A, Zhang F, Eliseenkova AV, Yayon A, Basilico C, Linhardt RJ, Schlessinger J, Mohammadi M.  (2004)  Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity..  Proc Natl Acad Sci USA,  101  (4): (935-40).  [PMID:14732692]
3. Zhou W, Hur W, McDermott U, Dutt A, Xian W, Ficarro SB, Zhang J, Sharma SV, Brugge J, Meyerson M et al..  (2010)  A structure-guided approach to creating covalent FGFR inhibitors..  Chem Biol,  17  (3): (285-95).  [PMID:20338520]
4. Adrián FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, Zhang G, Hur W, Ding S, Manley P et al..  (2006)  Allosteric inhibitors of Bcr-abl-dependent cell proliferation..  Nat Chem Biol,  2  (2): (95-102).  [PMID:16415863]
5. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C et al..  (2007)  Patterns of somatic mutation in human cancer genomes..  Nature,  446  (7132): (153-8).  [PMID:17344846]
6. Goriely A, Hansen RM, Taylor IB, Olesen IA, Jacobsen GK, McGowan SJ, Pfeifer SP, McVean GA, Rajpert-De Meyts E, Wilkie AO.  (2009)  Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors..  Nat Genet,  41  (11): (1247-52).  [PMID:19855393]
7. Chesi M, Nardini E, Brents LA, Schröck E, Ried T, Kuehl WM, Bergsagel PL.  (1997)  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3..  Nat Genet,  16  (3): (260-4).  [PMID:9207791]
8. Klutchko SR, Zhou H, Winters RT, Tran TP, Bridges AJ, Althaus IW, Amato DM, Elliott WL, Ellis PA, Meade MA et al..  (2006)  Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors..  J Med Chem,  49  (4): (1475-85).  [PMID:16480284]
9. Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ et al..  (2006)  Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity..  J Med Chem,  49  (12): (3563-80).  [PMID:16759099]
10. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, Brueggen J, Jensen MR, Schnell C, Schmid H et al..  (2011)  Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase..  J Med Chem,  54  (20): (7066-83).  [PMID:21936542]
11. Cheng H, Li C, Bailey S, Baxi SM, Goulet L, Guo L, Hoffman J, Jiang Y, Johnson TO, Johnson TW et al..  (2013)  Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design..  ACS Med Chem Lett,  4  (1): (91-7).  [PMID:24900568]
12. Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G, Hatch H et al..  (2010)  MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor..  Cancer Res,  70  (4): (1524-33).  [PMID:20145145]
13. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA.  (2008)  Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases..  Nat Chem Biol,  4  (11): (691-9).  [PMID:18849971]
14. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q et al..  (2009)  AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)..  Blood,  114  (14): (2984-92).  [PMID:19654408]
15. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK.  (2005)  CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma..  Blood,  105  (7): (2941-8).  [PMID:15598814]
16. Zhao G, Li WY, Chen D, Henry JR, Li HY, Chen Z, Zia-Ebrahimi M, Bloem L, Zhai Y, Huss K et al..  (2011)  A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models..  Mol Cancer Ther,  10  (11): (2200-10).  [PMID:21900693]
17. Hall MD, Salam NK, Hellawell JL, Fales HM, Kensler CB, Ludwig JA, Szakács G, Hibbs DE, Gottesman MM.  (2009)  Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells..  J Med Chem,  52  (10): (3191-204).  [PMID:19397322]
18. Lafleur K, Huang D, Zhou T, Caflisch A, Nevado C.  (2009)  Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4)..  J Med Chem,  52  (20): (6433-46).  [PMID:19788238]
19. Pandey A, Volkots DL, Seroogy JM, Rose JW, Yu JC, Lambing JL, Hutchaleelaha A, Hollenbach SJ, Abe K, Giese NA et al..  (2002)  Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family..  J Med Chem,  45  (17): (3772-93).  [PMID:12166950]
20. Hudkins RL, Becknell NC, Zulli AL, Underiner TL, Angeles TS, Aimone LD, Albom MS, Chang H, Miknyoczki SJ, Hunter K et al..  (2012)  Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent..  J Med Chem,  55  (2): (903-13).  [PMID:22148921]
21. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, Shokat KM.  (2009)  Inhibitor hijacking of Akt activation..  Nat Chem Biol,  5  (7): (484-93).  [PMID:19465931]
22. Hennequin LF, Thomas AP, Johnstone C, Stokes ES, Plé PA, Lohmann JJ, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO et al..  (1999)  Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors..  J Med Chem,  42  (26): (5369-89).  [PMID:10639280]
23. Hagel M, Miduturu C, Sheets M, Rubin N, Weng W, Stransky N, Bifulco N, Kim JL, Hodous B, Brooijmans N et al..  (2015)  First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway..  Cancer Discov,  5  (4): (424-37).  [PMID:25776529]
24. Aronov AM, Tang Q, Martinez-Botella G, Bemis GW, Cao J, Chen G, Ewing NP, Ford PJ, Germann UA, Green J et al..  (2009)  Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control..  J Med Chem,  52  (20): (6362-8).  [PMID:19827834]
25. Hobson AD, Harris CM, van der Kam EL, Turner SC, Abibi A, Aguirre AL, Bousquet P, Kebede T, Konopacki DB, Gintant G et al..  (2015)  Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders..  J Med Chem,  58  (23): (9154-70).  [PMID:26509640]
26. Hall TG, Yu Y, Eathiraj S, Wang Y, Savage RE, Lapierre JM, Schwartz B, Abbadessa G.  (2016)  Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation..  PLoS ONE,  11  (9): (e0162594).  [PMID:27627808]
27. Brameld KA, Owens TD, Verner E, Venetsanakos E, Bradshaw JM, Phan VT, Tam D, Leung K, Shu J, LaStant J et al..  (2017)  Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors..  J Med Chem,  60  (15): (6516-6527).  [PMID:28665128]
28. Burger MT, Nishiguchi G, Han W, Lan J, Simmons R, Atallah G, Ding Y, Tamez V, Zhang Y, Mathur M et al..  (2015)  Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies..  J Med Chem,  58  (21): (8373-86).  [PMID:26505898]
29. Zhang H, Xu L, Qin X, Chen X, Cong H, Hu L, Chen L, Miao Z, Zhang W, Cai Z et al..  (2019)  N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK-632) Analogues as Novel Necroptosis Inhibitors by Targeting Receptor-Interacting Protein Kinase 3 (RIPK3): Synthesis, Structure-Activity Relationships, and in Vivo Efficacy..  J Med Chem,  62  (14): (6665-6681).  [PMID:31095385]
30. Pomel V, Klicic J, Covini D, Church DD, Shaw JP, Roulin K, Burgat-Charvillon F, Valognes D, Camps M, Chabert C et al..  (2006)  Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma..  J Med Chem,  49  (13): (3857-71).  [PMID:16789742]
31. Ren X, Pan X, Zhang Z, Wang D, Lu X, Li Y, Wen D, Long H, Luo J, Feng Y et al..  (2013)  Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib..  J Med Chem,  56  (3): (879-94).  [PMID:23301703]
32. Czako B, Marszalek JR, Burke JP, Mandal P, Leonard PG, Cross JB, Mseeh F, Jiang Y, Chang EQ, Suzuki E et al..  (2020)  Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R..  J Med Chem,  129  (3): (589-97).  [PMID:32787110]
33. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-O M.  (2007)  Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21..  J Biol Chem,  282  (37): (26687-26695).  [PMID:17623664]
34. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G..  (2004)  SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity..  Bioorg Med Chem Lett,  14  (13): (3601-3605).  [PMID:15177483]
35. Rewcastle GW, Murray DK, Elliott WL, Fry DW, Howard CT, Nelson JM, Roberts BJ, Vincent PW, Showalter HD, Winters RT, Denny WA..  (1998)  Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors..  J Med Chem,  41  (5): (742-751).  [PMID:9513602]
36. Borzilleri RM, Zheng X, Qian L, Ellis C, Cai ZW, Wautlet BS, Mortillo S, Jeyaseelan R, Kukral DW, Fura A, Kamath A, Vyas V, Tokarski JS, Barrish JC, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS..  (2005)  Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors..  J Med Chem,  48  (12): (3991-4008).  [PMID:15943473]
37. VanderWel SN, Harvey PJ, McNamara DJ, Repine JT, Keller PR, Quin J, Booth RJ, Elliott WL, Dobrusin EM, Fry DW, Toogood PL..  (2005)  Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4..  J Med Chem,  48  (7): (2371-2387).  [PMID:15801830]
38. Vendôme J, Letard S, Martin F, Svinarchuk F, Dubreuil P, Auclair C, Le Bret M..  (2005)  Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases..  J Med Chem,  48  (20): (6194-6201).  [PMID:16190746]
39. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Neumann U, Rucklin G..  (2006)  Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity..  Bioorg Med Chem Lett,  16  (2): (262-266).  [PMID:16249085]
40. McDermott LA, Higgins B, Simcox M, Luk KC, Nevins T, Kolinsky K, Smith M, Yang H, Li JK, Chen Y, Ke J, Mallalieu N, Egan T, Kolis S, Railkar A, Gerber L, Liu JJ, Konzelmann F, Zhang Z, Flynn T, Morales O, Chen Y..  (2006)  Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis..  Bioorg Med Chem Lett,  16  (7): (1950-1953).  [PMID:16460940]
41. Zhao H, Serby MD, Xin Z, Szczepankiewicz BG, Liu M, Kosogof C, Liu B, Nelson LT, Johnson EF, Wang S, Pederson T, Gum RJ, Clampit JE, Haasch DL, Abad-Zapatero C, Fry EH, Rondinone C, Trevillyan JM, Sham HL, Liu G..  (2006)  Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors..  J Med Chem,  49  (15): (4455-4458).  [PMID:16854050]
42. Potashman MH, Bready J, Coxon A, DeMelfi TM, DiPietro L, Doerr N, Elbaum D, Estrada J, Gallant P, Germain J, Gu Y, Harmange JC, Kaufman SA, Kendall R, Kim JL, Kumar GN, Long AM, Neervannan S, Patel VF, Polverino A, Rose P, Plas Sv, Whittington D, Zanon R, Zhao H..  (2007)  Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors..  J Med Chem,  50  (18): (4351-4373).  [PMID:17696416]
43. Manetti F, Santucci A, Locatelli GA, Maga G, Spreafico A, Serchi T, Orlandini M, Bernardini G, Caradonna NP, Spallarossa A, Brullo C, Schenone S, Bruno O, Ranise A, Bondavalli F, Hoffmann O, Bologna M, Angelucci A, Botta M..  (2007)  Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice..  J Med Chem,  50  (23): (5579-5588).  [PMID:17929792]
44. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J..  (2007)  Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling..  Proc Natl Acad Sci U S A,  104  (50): (19936-19941).  [PMID:18077425]
45. Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, Ruiz C, Schürer SC, Inoue T, Rao PV, Schröter T, Lograsso P..  (2008)  Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors..  J Med Chem,  51  (21): (6642-6645).  [PMID:18834107]
46. Shomin CD, Meyer SC, Ghosh I..  (2009)  Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): optimization and selectivity profiling..  Bioorg Med Chem,  17  (17): (6196-6202).  [PMID:19674907]
47. Wee XK, Yeo WK, Zhang B, Tan VB, Lim KM, Tay TE, Go ML..  (2009)  Synthesis and evaluation of functionalized isoindigos as antiproliferative agents..  Bioorg Med Chem,  17  (21): (7562-7571).  [PMID:19783149]
48. Qiao L, Choi S, Case A, Gainer TG, Seyb K, Glicksman MA, Lo DC, Stein RL, Cuny GD..  (2009)  Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors..  Bioorg Med Chem Lett,  19  (21): (6122-6126).  [PMID:19783434]
49. Deng X, Lim SM, Zhang J, Gray NS..  (2010)  Broad spectrum alkynyl inhibitors of T315I Bcr-Abl..  Bioorg Med Chem Lett,  20  (14): (4196-4200).  [PMID:20541934]
50. Choi HG, Ren P, Adrian F, Sun F, Lee HS, Wang X, Ding Q, Zhang G, Xie Y, Zhang J, Liu Y, Tuntland T, Warmuth M, Manley PW, Mestan J, Gray NS, Sim T..  (2010)  A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl..  J Med Chem,  53  (15): (5439-5448).  [PMID:20604564]
51. Probst GD, Bowers S, Sealy JM, Truong AP, Hom RK, Galemmo RA, Konradi AW, Sham HL, Quincy DA, Pan H, Yao N, Lin M, Tóth G, Artis DR, Zmolek W, Wong K, Qin A, Lorentzen C, Nakamura DF, Quinn KP, Sauer JM, Powell K, Ruslim L, Wright S, Chereau D, Ren Z, Anderson JP, Bard F, Yednock TA, Griswold-Prenner I..  (2011)  Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration..  Bioorg Med Chem Lett,  21  (1): (315-319).  [PMID:21112785]
52. Kim MH, Kim M, Yu H, Kim H, Yoo KH, Sim T, Hah JM..  (2011)  Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells..  Bioorg Med Chem,  19  (6): (1915-1923).  [PMID:21353571]
53. Kim H, Kim M, Lee J, Yu H, Hah JM..  (2011)  Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells..  Bioorg Med Chem,  19  (22): (6760-6767).  [PMID:22014755]
54. Ishikawa T, Seto M, Banno H, Kawakita Y, Oorui M, Taniguchi T, Ohta Y, Tamura T, Nakayama A, Miki H, Kamiguchi H, Tanaka T, Habuka N, Sogabe S, Yano J, Aertgeerts K, Kamiyama K..  (2011)  Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold..  J Med Chem,  54  (23): (8030-8050).  [PMID:22003817]
55. Heidary DK, Huang G, Boucher D, Ma J, Forster C, Grey R, Xu J, Arnost M, Choquette D, Chen G, Zhou JH, Yao YM, Ball ED, Namchuk M, Davies RJ, Henkel G..  (2012)  VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia..  J Med Chem,  55  (2): (725-734).  [PMID:22221201]
56. Cuny GD, Ulyanova NP, Patnaik D, Liu JF, Lin X, Auerbach K, Ray SS, Xian J, Glicksman MA, Stein RL, Higgins JM..  (2012)  Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors..  Bioorg Med Chem Lett,  22  (5): (2015-2019).  [PMID:22335895]
57. Lo Monte F, Kramer T, Gu J, Anumala UR, Marinelli L, La Pietra V, Novellino E, Franco B, Demedts D, Van Leuven F, Fuertes A, Dominguez JM, Plotkin B, Eldar-Finkelman H, Schmidt B..  (2012)  Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α..  J Med Chem,  55  (9): (4407-4424).  [PMID:22533818]
58. Illig CR, Manthey CL, Wall MJ, Meegalla SK, Chen J, Wilson KJ, Ballentine SK, Desjarlais RL, Schubert C, Crysler CS, Chen Y, Molloy CJ, Chaikin MA, Donatelli RR, Yurkow E, Zhou Z, Player MR, Tomczuk BE..  (2011)  Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141)..  J Med Chem,  54  (22): (7860-7883).  [PMID:22039836]
59. Reith AD, Bamborough P, Jandu K, Andreotti D, Mensah L, Dossang P, Choi HG, Deng X, Zhang J, Alessi DR, Gray NS..  (2012)  GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor..  Bioorg Med Chem Lett,  22  (17): (5625-5629).  [PMID:22863203]
60. Amombo GM, Kramer T, Lo Monte F, Göring S, Fach M, Smith S, Kolb S, Schubenel R, Baumann K, Schmidt B..  (2012)  Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3..  Bioorg Med Chem Lett,  22  (24): (7634-7640).  [PMID:23107479]
61. Mortensen DS, Sapienza J, Lee BG, Perrin-Ninkovic SM, Harris R, Shevlin G, Parnes JS, Whitefield B, Hickman M, Khambatta G, Bisonette RR, Peng S, Gamez JC, Leisten J, Narla RK, Fultz KE, Sankar S..  (2013)  Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase..  Bioorg Med Chem Lett,  23  (6): (1588-1591).  [PMID:23414803]
62. Pauwels D, Klaassen H, Lahortiga I, Kilonda A, Jacobs K, Sweron B, Corbau R, Chaltin P, Marchand A, Cools J..  (2013)  Identification of novel FLT3 kinase inhibitors..  Eur J Med Chem,  63  (713-721).  [PMID:23567961]
63. Bowers S, Truong AP, Ye M, Aubele DL, Sealy JM, Neitz RJ, Hom RK, Chan W, Dappen MS, Galemmo RA, Konradi AW, Sham HL, Zhu YL, Beroza P, Tonn G, Zhang H, Hoffman J, Motter R, Fauss D, Tanaka P, Bova MP, Ren Z, Tam D, Ruslim L, Baker J, Pandya D, Diep L, Fitzgerald K, Artis DR, Anderson JP, Bergeron M..  (2013)  Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors..  Bioorg Med Chem Lett,  23  (9): (2743-2749).  [PMID:23522834]
64. Blake JF, Gaudino JJ, De Meese J, Mohr P, Chicarelli M, Tian H, Garrey R, Thomas A, Siedem CS, Welch MB, Kolakowski G, Kaus R, Burkard M, Martinson M, Chen H, Dean B, Dudley DA, Gould SE, Pacheco P, Shahidi-Latham S, Wang W, West K, Yin J, Moffat J, Schwarz JB..  (2014)  Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2..  Bioorg Med Chem Lett,  24  (12): (2635-2639).  [PMID:24813737]
65. Menet CJ, Fletcher SR, Van Lommen G, Geney R, Blanc J, Smits K, Jouannigot N, Deprez P, van der Aar EM, Clement-Lacroix P, Lepescheux L, Galien R, Vayssiere B, Nelles L, Christophe T, Brys R, Uhring M, Ciesielski F, Van Rompaey L..  (2014)  Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634..  J Med Chem,  57  (22): (9323-9342).  [PMID:25369270]
66. Muth F, Günther M, Bauer SM, Döring E, Fischer S, Maier J, Drückes P, Köppler J, Trappe J, Rothbauer U, Koch P, Laufer SA..  (2015)  Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases..  J Med Chem,  58  (1): (443-456).  [PMID:25475894]
67. Roth GJ, Binder R, Colbatzky F, Dallinger C, Schlenker-Herceg R, Hilberg F, Wollin SL, Kaiser R..  (2015)  Nintedanib: from discovery to the clinic..  J Med Chem,  58  (3): (1053-1063).  [PMID:25474320]
68. Abdel-Magid AF..  (2015)  Fibroblast Growth Factor Receptor 3 (FGF-R3): A Promising Therapeutic Target for the Treatment of Bladder Cancer..  ACS Med Chem Lett,  6  (4): (369-370).  [PMID:25941550]
69. Choi HS, Rucker PV, Wang Z, Fan Y, Albaugh P, Chopiuk G, Gessier F, Sun F, Adrian F, Liu G, Hood T, Li N, Jia Y, Che J, McCormack S, Li A, Li J, Steffy A, Culazzo A, Tompkins C, Phung V, Kreusch A, Lu M, Hu B, Chaudhary A, Prashad M, Tuntland T, Liu B, Harris J, Seidel HM, Loren J, Molteni V..  (2015)  (R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors..  ACS Med Chem Lett,  6  (5): (562-567).  [PMID:26005534]
70. Charnley AK, Convery MA, Lakdawala Shah A, Jones E, Hardwicke P, Bridges A, Ouellette M, Totoritis R, Schwartz B, King BW, Wisnoski DD, Kang J, Eidam PM, Votta BJ, Gough PJ, Marquis RW, Bertin J, Casillas L..  (2015)  Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity..  Bioorg Med Chem,  23  (21): (7000-7006).  [PMID:26455654]
71. Simon-Szabó L, Kokas M, Greff Z, Boros S, Bánhegyi P, Zsákai L, Szántai-Kis C, Vantus T, Mandl J, Bánhegyi G, Vályi-Nagy I, Őrfi L, Ullrich A, Csala M, Kéri G..  (2016)  Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes..  Bioorg Med Chem Lett,  26  (2): (424-428).  [PMID:26704265]
72. Aman W, Lee J, Kim M, Yang S, Jung H, Hah JM..  (2016)  Discovery of highly selective CRAF inhibitors, 3-carboxamido-2H-indazole-6-arylamide: In silico FBLD design, synthesis and evaluation..  Bioorg Med Chem Lett,  26  (4): (1188-1192).  [PMID:26810260]
73. Schiemann K, Mallinger A, Wienke D, Esdar C, Poeschke O, Busch M, Rohdich F, Eccles SA, Schneider R, Raynaud FI, Czodrowski P, Musil D, Schwarz D, Urbahns K, Blagg J..  (2016)  Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore..  Bioorg Med Chem Lett,  26  (5): (1443-1451).  [PMID:26852363]
74. Fan J, Dai Y, Shao J, Peng X, Wang C, Cao S, Zhao B, Ai J, Geng M, Duan W..  (2016)  Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors..  Bioorg Med Chem Lett,  26  (11): (2594-2599).  [PMID:27117427]
75. Schroeder RL, Goyal N, Bratton M, Townley I, Pham NA, Tram P, Stone T, Geathers J, Nguyen K, Sridhar J..  (2016)  Identification of quinones as novel PIM1 kinase inhibitors..  Bioorg Med Chem Lett,  26  (13): (3187-3191).  [PMID:27173800]
76. Kim H, Lee C, Yang JS, Choi S, Park CH, Kang JS, Oh SJ, Yun J, Kim MH, Han G..  (2016)  Structural modifications at the 6-position of thieno[2,3-d]pyrimidines and their effects on potency at FLT3 for treatment of acute myeloid leukemia..  Eur J Med Chem,  120  (74-85).  [PMID:27187860]
77. Zhu W, Chen H, Wang Y, Wang J, Peng X, Chen X, Gao Y, Li C, He Y, Ai J, Geng M, Zheng M, Liu H..  (2017)  Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer..  J Med Chem,  60  (14): (6018-6035).  [PMID:28714692]
78. Zhang Y, Chen Y, Zhang D, Wang L, Lu T, Jiao Y..  (2018)  Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines..  J Med Chem,  61  (1): (140-157).  [PMID:29189002]
79. Zhang H, Wu W, Feng C, Liu Z, Bai E, Wang X, Lei M, Cheng H, Feng H, Shi J, Wang J, Zhang Z, Jin T, Chen S, Hu S, Zhu Y..  (2017)  Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants..  Eur J Med Chem,  135  (12-23).  [PMID:28426996]
80. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N..  (2017)  Discovery of DS79182026: A potent orally active hepcidin production inhibitor..  Bioorg Med Chem Lett,  27  (16): (3716-3722).  [PMID:28705644]
81. Patel S, Meilandt WJ, Erickson RI, Chen J, Deshmukh G, Estrada AA, Fuji RN, Gibbons P, Gustafson A, Harris SF, Imperio J, Liu W, Liu X, Liu Y, Lyssikatos JP, Ma C, Yin J, Lewcock JW, Siu M..  (2017)  Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's Disease..  J Med Chem,  60  (19): (8083-8102).  [PMID:28929759]
82. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N..  (2017)  Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives..  Bioorg Med Chem Lett,  27  (23): (5252-5257).  [PMID:29079471]
83. Farag AK, Elkamhawy A, Londhe AM, Lee KT, Pae AN, Roh EJ..  (2017)  Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders..  Eur J Med Chem,  141  (657-675).  [PMID:29107425]
84. Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W..  (2018)  Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer..  Bioorg Med Chem,  26  (3): (590-602).  [PMID:29289448]
85. Assadieskandar A, Yu C, Maisonneuve P, Liu X, Chen YC, Prakash GKS, Kurinov I, Sicheri F, Zhang C..  (2018)  Effects of rigidity on the selectivity of protein kinase inhibitors..  Eur J Med Chem,  146  (519-528).  [PMID:29407977]
86. Wang Q, Liu F, Qi S, Qi Z, Yan XE, Wang B, Wang A, Wang W, Chen C, Liu X, Jiang Z, Hu Z, Wang L, Wang W, Ren T, Zhang S, Yun CH, Liu Q, Liu J..  (2018)  Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia..  Eur J Med Chem,  150  (366-384).  [PMID:29544149]
87. He LJ, Yang DL, Li SQ, Zhang YJ, Tang Y, Lei J, Frett B, Lin HK, Li HY, Chen ZZ, Xu ZG..  (2018)  Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells..  Bioorg Med Chem,  26  (14): (3899-3908).  [PMID:29921474]
88. Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W..  (2018)  Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors..  Bioorg Med Chem Lett,  28  (20): (3356-3362).  [PMID:30227946]
89. Wang B, Wu J, Wu Y, Chen C, Zou F, Wang A, Wu H, Hu Z, Jiang Z, Liu Q, Wang W, Zhang Y, Liu F, Zhao M, Hu J, Huang T, Ge J, Wang L, Ren T, Wang Y, Liu J, Liu Q..  (2018)  Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor..  Eur J Med Chem,  158  (896-916).  [PMID:30253346]
90. Dodo K, Kuboki E, Shimizu T, Imamura R, Magarisawa M, Takahashi M, Tokuhiro T, Yotsumoto S, Asano K, Nakao S, Terayama N, Suda T, Tanaka M, Sodeoka M..  (2019)  Development of a Water-Soluble Indolylmaleimide Derivative IM-93 Showing Dual Inhibition of Ferroptosis and NETosis..  ACS Med Chem Lett,  10  (9): (1272-1278).  [PMID:31531196]
91. Zhang Q, Hu X, Wan G, Wang J, Li L, Wu X, Liu Z, Yu L..  (2019)  Discovery of 3-(((9H-purin-6-yl)amino)methyl)-4,6-dimethylpyridin-2(1H)-one derivatives as novel tubulin polymerization inhibitors for treatment of cancer..  Eur J Med Chem,  184  (111728-111728).  [PMID:31610375]
92. Baska F, Sipos A, Őrfi Z, Nemes Z, Dobos J, Szántai-Kis C, Szabó E, Szénási G, Dézsi L, Hamar P, Cserepes MT, Tóvári J, Garamvölgyi R, Krekó M, Őrfi L..  (2019)  Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases..  Eur J Med Chem,  184  (111710-111710).  [PMID:31614258]
93. Narayan S, Ramisetti S, Jaiswal AS, Law BK, Singh-Pillay A, Singh P, Amin S, Sharma AK..  (2019)  ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells..  Eur J Med Chem,  161  (456-467).  [PMID:30384048]
94. Wang Y, Dou X, Jiang L, Jin H, Zhang L, Zhang L, Liu Z..  (2019)  Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia..  Eur J Med Chem,  171  (221-234).  [PMID:30925338]
95. Liang X, Zang J, Li X, Tang S, Huang M, Geng M, Chou CJ, Li C, Cao Y, Xu W, Liu H, Zhang Y..  (2019)  Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies..  J Med Chem,  62  (8): (3898-3923).  [PMID:30901208]
96. Harris PA, Faucher N, George N, Eidam PM, King BW, White GV, Anderson NA, Bandyopadhyay D, Beal AM, Beneton V, Berger SB, Campobasso N, Campos S, Capriotti CA, Cox JA, Daugan A, Donche F, Fouchet MH, Finger JN, Geddes B, Gough PJ, Grondin P, Hoffman BL, Hoffman SJ, Hutchinson SE, Jeong JU, Jigorel E, Lamoureux P, Leister LK, Lich JD, Mahajan MK, Meslamani J, Mosley JE, Nagilla R, Nassau PM, Ng SL, Ouellette MT, Pasikanti KK, Potvain F, Reilly MA, Rivera EJ, Sautet S, Schaeffer MC, Sehon CA, Sun H, Thorpe JH, Totoritis RD, Ward P, Wellaway N, Wisnoski DD, Woolven JM, Bertin J, Marquis RW..  (2019)  Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase..  J Med Chem,  62  (10): (5096-5110).  [PMID:31013427]
97. Lin X, Yosaatmadja Y, Kalyukina M, Middleditch MJ, Zhang Z, Lu X, Ding K, Patterson AV, Smaill JB, Squire CJ..  (2019)  Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4..  ACS Med Chem Lett,  10  (8): (1180-1186).  [PMID:31413803]
98. Szabadkai I, Torka R, Garamvölgyi R, Baska F, Gyulavári P, Boros S, Illyés E, Choidas A, Ullrich A, Őrfi L..  (2018)  Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors..  J Med Chem,  61  (14): (6277-6292).  [PMID:29928803]
99. Wang X, Yu C, Wang C, Ma Y, Wang T, Li Y, Huang Z, Zhou M, Sun P, Zheng J, Yang S, Fan Y, Xiang R..  (2019)  Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer..  Eur J Med Chem,  181  (111535-111535).  [PMID:31376566]
100. Zhao L, Li Y, Wang Y, Qiao Z, Miao Z, Yang J, Huang L, Tian C, Li L, Chen D, Yang S..  (2019)  Discovery of 4H-Chromen-4-one Derivatives as a New Class of Selective Rho Kinase (ROCK) Inhibitors, which Showed Potent Activity in ex Vivo Diabetic Retinopathy Models..  J Med Chem,  62  (23): (10691-10710).  [PMID:31693351]
101. Jang J, Son JB, To C, Bahcall M, Kim SY, Kang SY, Mushajiang M, Lee Y, Jänne PA, Choi HG, Gray NS..  (2017)  Discovery of a potent dual ALK and EGFR T790M inhibitor..  Eur J Med Chem,  136  (497-510).  [PMID:28528303]
102. Wang Y, Li L, Fan J, Dai Y, Jiang A, Geng M, Ai J, Duan W..  (2018)  Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors..  J Med Chem,  61  (20): (9085-9104).  [PMID:29522671]
103. Bronner SM, Merrick KA, Murray J, Salphati L, Moffat JG, Pang J, Sneeringer CJ, Dompe N, Cyr P, Purkey H, Boenig GL, Li J, Kolesnikov A, Larouche-Gauthier R, Lai KW, Shen X, Aubert-Nicol S, Chen YC, Cheong J, Crawford JJ, Hafner M, Haghshenas P, Jakalian A, Leclerc JP, Lim NK, O'Brien T, Plise EG, Shalan H, Sturino C, Wai J, Xiao Y, Yin J, Zhao L, Gould S, Olivero A, Heffron TP..  (2019)  Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma..  Bioorg Med Chem Lett,  29  (16): (2294-2301).  [PMID:31307887]
104. Oukoloff K, Coquelle N, Bartolini M, Naldi M, Le Guevel R, Bach S, Josselin B, Ruchaud S, Catto M, Pisani L, Denora N, Iacobazzi RM, Silman I, Sussman JL, Buron F, Colletier JP, Jean L, Routier S, Renard PY..  (2019)  Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3..  Eur J Med Chem,  168  (58-77).  [PMID:30798053]
105. Heider F, Ansideri F, Tesch R, Pantsar T, Haun U, Döring E, Kudolo M, Poso A, Albrecht W, Laufer SA, Koch P..  (2019)  Pyridinylimidazoles as dual glycogen synthase kinase 3β/p38α mitogen-activated protein kinase inhibitors..  Eur J Med Chem,  175  (309-329).  [PMID:31096153]
106. Lu X, Chen H, Patterson AV, Smaill JB, Ding K..  (2019)  Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects..  J Med Chem,  62  (6): (2905-2915).  [PMID:30403487]
107. Wang Q, Dai Y, Ji Y, Shi H, Guo Z, Chen D, Chen Y, Peng X, Gao Y, Wang X, Chen L, Jiang Y, Geng M, Shen J, Ai J, Xiong B..  (2019)  Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma..  Eur J Med Chem,  163  (671-689).  [PMID:30572178]
108. Ikegashira K, Ikenogami T, Yamasaki T, Oka T, Hase Y, Miyagawa N, Inagaki K, Kawahara I, Koga Y, Hashimoto H..  (2019)  Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952..  Bioorg Med Chem Lett,  29  (7): (873-877).  [PMID:30755337]
109. Mathison CJN, Chianelli D, Rucker PV, Nelson J, Roland J, Huang Z, Yang Y, Jiang J, Xie YF, Epple R, Bursulaya B, Lee C, Gao MY, Shaffer J, Briones S, Sarkisova Y, Galkin A, Li L, Li N, Li C, Hua S, Kasibhatla S, Kinyamu-Akunda J, Kikkawa R, Molteni V, Tellew JE..  (2020)  Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma..  ACS Med Chem Lett,  11  (4): (558-565).  [PMID:32292564]
110. Kuriwaki I, Kameda M, Hisamichi H, Kikuchi S, Iikubo K, Kawamoto Y, Moritomo H, Kondoh Y, Amano Y, Tateishi Y, Echizen Y, Iwai Y, Noda A, Tomiyama H, Suzuki T, Hirano M..  (2020)  Structure-based drug design of 1,3,5-triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2..  Bioorg Med Chem,  28  (10): (115453-115453).  [PMID:32278710]
111. Hamilton GL,Chen H,Deshmukh G,Eigenbrot C,Fong R,Johnson A,Kohli PB,Lupardus PJ,Liederer BM,Ramaswamy S,Wang H,Wang J,Xu Z,Zhu Y,Vucic D,Patel S.  (2019)  Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group..  Bioorg Med Chem Lett,  29  (12.0): (1497-1501).  [PMID:31000154]
112. Rezende Miranda R,Fu Y,Chen X,Perino J,Cao P,Carpten J,Chen Y,Zhang C.  (2020)  Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma..  J Med Chem,  63  (20): (11484-11497).  [PMID:33030342]
113. Ding X,Stasi LP,Ho MH,Zhao B,Wang H,Long K,Xu Q,Sang Y,Sun C,Hu H,Yu H,Wan Z,Wang L,Edge C,Liu Q,Li Y,Dong K,Guan X,Tattersall FD,Reith AD,Ren F.  (2018)  Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors..  Bioorg Med Chem Lett,  28  (9.0): (1615-1620).  [PMID:29588215]
114. Fairhurst RA,Knoepfel T,Buschmann N,Leblanc C,Mah R,Todorov M,Nimsgern P,Ripoche S,Niklaus M,Warin N,Luu VH,Madoerin M,Wirth J,Graus-Porta D,Weiss A,Kiffe M,Wartmann M,Kinyamu-Akunda J,Sterker D,Stamm C,Adler F,Buhles A,Schadt H,Couttet P,Blank J,Galuba I,Trappe J,Voshol J,Ostermann N,Zou C,Berghausen J,Del Rio Espinola A,Jahnke W,Furet P.  (2020)  Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4..  J Med Chem,  63  (21.0): (12542-12573).  [PMID:32930584]
115. Kuriwaki I,Kameda M,Iikubo K,Hisamichi H,Kawamoto Y,Kikuchi S,Moritomo H,Kondoh Y,Terasaka T,Amano Y,Tateishi Y,Echizen Y,Iwai Y,Noda A,Tomiyama H,Nakazawa T,Hirano M.  (2021)  Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency..  Bioorg Med Chem,  33  (116019-116019).  [PMID:33486159]
116. Chen X,Liu Y,Zhang L,Chen D,Dong Z,Zhao C,Liu Z,Xia Q,Wu J,Chen Y,Zheng X,Cai Y.  (2021)  Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer..  Eur J Med Chem,  214  (113219-113219).  [PMID:33618175]
117. Yang J,Chen K,Zhang G,Yang QY,Li YS,Huang SZ,Wang YL,Yang W,Jiang XJ,Yan HX,Zhu JQ,Xiang R,Luo YF,Li WM,Wei YQ,Li LL,Yang SY.  (2018)  Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants..  Eur J Med Chem,  143  (1148-1164).  [PMID:29133048]
118. Liang X, Tang S, Liu X, Liu Y, Xu Q, Wang X, Saidahmatov A, Li C, Wang J, Zhou Y, Zhang Y, Geng M, Huang M, Liu H..  (2022)  Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors..  J Med Chem,  65  (2.0): (1243-1264).  [PMID:33586434]
119. Thompson, L M LM and 6 more authors..  (1991)  A gene encoding a fibroblast growth factor receptor isolated from the Huntington disease gene region of human chromosome 4..  Genomics,      [PMID:1664411]
120. Keegan, K K, Johnson, D E DE, Williams, L T LT and Hayman, M J MJ..  (1991)  Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3..  Proceedings of the National Academy of Sciences of the United States of America,    (15):   [PMID:1847508]
121. Partanen, J J, Mäkelä, T P TP, Alitalo, R R, Lehväslaiho, H H and Alitalo, K K..  (1990)  Putative tyrosine kinases expressed in K-562 human leukemia cells..  Proceedings of the National Academy of Sciences of the United States of America,      [PMID:2247464]
122. Meyers, G A GA, Orlow, S J SJ, Munro, I R IR, Przylepa, K A KA and Jabs, E W EW..  (1995)  Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans..  Nature genetics,      [PMID:7493034]
123. Scotet, E E and Houssaint, E E..  (1995)  The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is not strictly tissue-specific..  Biochimica et biophysica acta,    (7):   [PMID:7495869]
124. Bellus, G A GA and 8 more authors..  (1995)  A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia..  Nature genetics,      [PMID:7670477]
125. Superti-Furga, A A and 6 more authors..  (1995)  A glycine 375-to-cysteine substitution in the transmembrane domain of the fibroblast growth factor receptor-3 in a newborn with achondroplasia..  European journal of pediatrics,      [PMID:7758520]
126. Tavormina, P L PL and 9 more authors..  (1995)  Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3..  Nature genetics,      [PMID:7773297]
127. Bellus, G A GA and 8 more authors..  (1995)  Achondroplasia is defined by recurrent G380R mutations of FGFR3..  American journal of human genetics,      [PMID:7847369]
128. Murgue, B B, Tsunekawa, S S, Rosenberg, I I, deBeaumont, M M and Podolsky, D K DK..  (1994)  Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium..  Cancer research,    (1):   [PMID:7923141]
129. Tavormina, P L PL and 5 more authors..  (1995)  Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I..  Human molecular genetics,      [PMID:8589699]
130. Webster, M K MK and Donoghue, D J DJ..  (1996)  Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia..  The EMBO journal,    (1):   [PMID:8599935]
131. Webster, M K MK, D'Avis, P Y PY, Robertson, S C SC and Donoghue, D J DJ..  (1996)  Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II..  Molecular and cellular biology,      [PMID:8754806]
132. Rousseau, F F and 6 more authors..  (1996)  Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1)..  Human molecular genetics,      [PMID:8845844]
133. Muenke, M M and 24 more authors..  (1997)  A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome..  American journal of human genetics,      [PMID:9042914]
134. Deutz-Terlouw, P P PP, Losekoot, M M, Aalfs, C M CM, Hennekam, R C RC and Bakker, E E..  (1998)  Asn540Thr substitution in the fibroblast growth factor receptor 3 tyrosine kinase domain causing hypochondroplasia..  Human mutation,      [PMID:9452043]
135. Hollway, G E GE and 5 more authors..  (1998)  Deafness due to Pro250Arg mutation of FGFR3..  Lancet (London, England),    (21):   [PMID:9525367]
136. Katsumata, N N and 7 more authors..  (1998)  G370C mutation in the FGFR3 gene in a Japanese patient with thanatophoric dysplasia..  Endocrine journal,      [PMID:9790257]
137. Lajeunie, E E and 5 more authors..  (1999)  Sex related expressivity of the phenotype in coronal craniosynostosis caused by the recurrent P250R FGFR3 mutation..  Journal of medical genetics,      [PMID:9950359]
138. Tavormina, P L PL and 13 more authors..  (1999)  A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene..  American journal of human genetics,      [PMID:10053006]
139. Grigelioniené, G G and 5 more authors..  (1998)  A novel missense mutation Ile538Val in the fibroblast growth factor receptor 3 in hypochondroplasia. Mutations in brief no. 122. Online..  Human mutation,      [PMID:10215410]
140. Brodie, S G SG and 5 more authors..  (1999)  Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by FGFR3 mutations..  American journal of medical genetics,    (11):   [PMID:10360402]
141. Cappellen, D D and 8 more authors..  (1999)  Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas..  Nature genetics,      [PMID:10471491]
142. Monsonego-Ornan, E E, Adar, R R, Feferman, T T, Segev, O O and Yayon, A A..  (2000)  The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation..  Molecular and cellular biology,      [PMID:10611230]
143. Kitoh, H H, Brodie, S G SG, Kupke, K G KG, Lachman, R S RS and Wilcox, W R WR..  (1998)  Lys650Met substitution in the tyrosine kinase domain of the fibroblast growth factor receptor gene causes thanatophoric dysplasia Type I. Mutations in brief no. 199. Online..  Human mutation,      [PMID:10671061]
144. Mortier, G G and 5 more authors..  (2000)  Clinical and radiographic features of a family with hypochondroplasia owing to a novel Asn540Ser mutation in the fibroblast growth factor receptor 3 gene..  Journal of medical genetics,      [PMID:10777366]
145. Bellus, G A GA and 10 more authors..  (2000)  Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype..  American journal of human genetics,      [PMID:11055896]
146. Hart, K C KC, Robertson, S C SC and Donoghue, D J DJ..  (2001)  Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation..  Molecular biology of the cell,      [PMID:11294897]
147. Sibley, K K, Cuthbert-Heavens, D D and Knowles, M A MA..  (2001)  Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma..  Oncogene,    (8):   [PMID:11314002]
148. Jang, J H JH, Shin, K H KH and Park, J G JG..  (2001)  Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers..  Cancer research,    (1):   [PMID:11325814]
149. Intini, D D and 6 more authors..  (2001)  Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14)..  British journal of haematology,      [PMID:11529856]
150. Terada, M M and 5 more authors..  (2001)  Fibroblast growth factor receptor 3 lacking the Ig IIIb and transmembrane domains secreted from human squamous cell carcinoma DJM-1 binds to FGFs..  Molecular cell biology research communications : MCBRC,      [PMID:11703096]
151. Lowry, R B RB, Jabs, E W EW, Graham, G E GE, Gerritsen, J J and Fleming, J J..  (2001)  Syndrome of coronal craniosynostosis, Klippel-Feil anomaly, and sprengel shoulder with and without Pro250Arg mutation in the FGFR3 gene..  American journal of medical genetics,    (22):   [PMID:11746040]
152. Monsonego-Ornan, E E, Adar, R R, Rom, E E and Yayon, A A..  (2002)  FGF receptors ubiquitylation: dependence on tyrosine kinase activity and role in downregulation..  FEBS letters,    (25):   [PMID:12297284]
153. Thauvin-Robinet, Christel C and 9 more authors..  (2003)  Hypochondroplasia and stature within normal limits: another family with an Asn540Ser mutation in the fibroblast growth factor receptor 3 gene..  American journal of medical genetics. Part A,    (15):   [PMID:12707965]
154. Agazie, Yehenew M YM, Movilla, Nieves N, Ischenko, Irene I and Hayman, Michael J MJ..  (2003)  The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3..  Oncogene,    (9):   [PMID:14534538]
155. L'Hôte, Corine G M CG and Knowles, Margaret A MA..  (2005)  Cell responses to FGFR3 signalling: growth, differentiation and apoptosis..  Experimental cell research,    (1):   [PMID:15748888]
156. Logié, Armelle A and 11 more authors..  (2005)  Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans..  Human molecular genetics,    (1):   [PMID:15772091]
157. Hillier, Ladeana W LW and 121 more authors..  (2005)  Generation and annotation of the DNA sequences of human chromosomes 2 and 4..  Nature,    (7):   [PMID:15815621]
158. Eswarakumar, V P VP, Lax, I I and Schlessinger, J J..  (2005)  Cellular signaling by fibroblast growth factor receptors..  Cytokine & growth factor reviews,      [PMID:15863030]
159. Ben-Zvi, Tal T, Yayon, Avner A, Gertler, Arieh A and Monsonego-Ornan, Efrat E..  (2006)  Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling..  Journal of cell science,    (15):   [PMID:16410555]
160. Rohmann, Edyta E and 21 more authors..  (2006)  Mutations in different components of FGF signaling in LADD syndrome..  Nature genetics,      [PMID:16501574]
161. Zhang, Xiuqin X and 5 more authors..  (2006)  Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family..  The Journal of biological chemistry,    (9):   [PMID:16597617]
162. Hafner, Christian C and 8 more authors..  (2006)  Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi..  The Journal of clinical investigation,      [PMID:16841094]
163. Toydemir, Reha M RM and 9 more authors..  (2006)  A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome..  American journal of human genetics,      [PMID:17033969]
164. Krejci, Pavel P and 6 more authors..  (2007)  Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins..  The Journal of biological chemistry,    (2):   [PMID:17145761]
165. Bonaventure, Jacky J, Gibbs, Linda L, Horne, William C WC and Baron, Roland R..  (2007)  The localization of FGFR3 mutations causing thanatophoric dysplasia type I differentially affects phosphorylation, processing and ubiquitylation of the receptor..  The FEBS journal,      [PMID:17509076]
166. Harada, Daisuke D and 6 more authors..  (2007)  Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1..  Bone,      [PMID:17561467]
167. Arnaud-López, L L, Fragoso, R R, Mantilla-Capacho, J J and Barros-Núñez, P P..  (2007)  Crouzon with acanthosis nigricans. Further delineation of the syndrome..  Clinical genetics,      [PMID:17935505]
168. Matsui, Junji J and 7 more authors..  (2008)  E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition..  International journal of cancer,    (1):   [PMID:17943726]
169. Dephoure, Noah N and 6 more authors..  (2008)  A quantitative atlas of mitotic phosphorylation..  Proceedings of the National Academy of Sciences of the United States of America,    (5):   [PMID:18669648]
170. Krejci, Pavel P and 8 more authors..  (2008)  Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage..  PloS one,      [PMID:19088846]
171. Salazar, Lisa L and 6 more authors..  (2009)  A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells..  Human molecular genetics,    (1):   [PMID:19286672]
172. Zhou, Houjiang H and 6 more authors..  (2013)  Toward a comprehensive characterization of a human cancer cell phosphoproteome..  Journal of proteome research,    (4):   [PMID:23186163]
173. Gozgit, Joseph M JM and 9 more authors..  (2013)  Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models..  Cancer chemotherapy and pharmacology,      [PMID:23468082]
174. Tabernero, Josep J and 18 more authors..  (2015)  Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology,    (20):   [PMID:26324363]
175. Wind, Sven and 7 more authors..  (2019)  Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib..  Clinical pharmacokinetics,      [PMID:31016670]
176. Rousseau, F F and 7 more authors..  (1994)  Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia..  Nature,    (15):   [PMID:8078586]
177. May-Dracka TL,Arduini R,Bertolotti-Ciarlet A,Bhisetti G,Brickelmaier M,Cahir-McFarland E,Enyedy I,Fontenot JD,Hesson T,Little K,Lyssikatos J,Marcotte D,McKee T,Murugan P,Patterson T,Peng H,Rushe M,Silvian L,Spilker K,Wu P,Xin Z,Burkly LC.  (2018)  Investigating small molecules to inhibit germinal center kinase-like kinase (GLK/MAP4K3) upstream of PKCθ phosphorylation: Potential therapy to modulate T cell dependent immunity..  Bioorg Med Chem Lett,  28  (10): (1964-1971).  [PMID:29636220]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.